MDC II TEST 2 PRACTICE SCRIPT 2026
QUESTIONS WITH SOLUTIONS
◉ Monoclonal antibodies(immunotherapy). Answer: Bind to target
antigens (often specific cell surface membrane proteins)
Prevents protein from functioning,
- prevents cell division. E.g- Rituximab (Rituxan)
◉ Tyrosine Kinase Inhibitors(immunotherapy). Answer: Inhibits
activation of tyrosine kinase inhibitors- disrupt growth and cellular
regulation of some types of cancer cells
◉ Epidermal Growth Factor/ Receptor Inhibitors(immunotherapy).
Answer: Block epidermal growth factor from binding to cell surface
receptor; prevents cancer cell division
◉ Vascular Endothelial Growth Factor/Receptor
Inhibitors(immunotherapy). Answer: prevents binding of VEGF with
its receptors on surfaces of endothelial cells present in blood
vessels. Prevents formation of new blood vessels within the tumor
◉ Multikinase Inhibitors (MKIs)(immunotherapy). Answer: Inhibit
activity of specific kinases in cancer cells and tumor blood vessels
,◉ Proteasome Inhibitor(immunotherapy). Answer: Prevents
formation of a large complex of proteins into cells; impair tumors
cellular regulation ability
◉ Angiogenesis inhibitors(immunotherapy). Answer: Targets
mammalian target of rapamycin; reduces concentration of vascular
endothelial growth factor, disrupts cell division.
◉ Photodynamic therapy. Answer: Selective destruction of cancer
cells via chemical reaction triggered by types of light
◉ Hormonal therapy. Answer: Changing usual hormone responses.
Some hormones make hormone sensitive tumors grow more rapidly
(Decreasing the hormone amounts to hormone sensitive tumors can
slow cancer growth rate).
Steroids, steroid analogues, enzyme inhibitors
◉ Surgical classification types. Answer: prophylaxis, diagnosis, cure,
control, palliation,assessing therapy effectiveness and
reconstruction
◉ Prophylaxis(Surgical classification type). Answer: remove
cancerous tissue to prevent cancer development
,◉ Diagnosis(Surgical classification type). Answer: removal for
testing or examination to rule out cancer "biopsy"
◉ Cure(Surgical classification type). Answer: removes all cancerous
tissue
◉ Control(Surgical classification type). Answer: removes part of
tumor when removal of entire tumor is impossible
◉ Palliation. Answer: surgery to provide symptom relief, is NOT
curative
◉ Assessing therapy effectiveness. Answer: (Surgical classification
type)
◉ Reconstruction(Surgical classification type). Answer: increases
function or appearance or both.
◉ S/E of Surgery. Answer: removal can lead to changes in
appearance, activity level, depression, grief, and decreased
enjoyment of life
, ◉ S/E of Radiation. Answer: Acute and long-term site-specific
changes, vary according to site, Local skin changes and hair loss,
altered taste sensations, Fatigue, Bone marrow suppression.
◉ S/E of Chemotherapy. Answer: extravasation,
infection risk,
bone marrow suppression,
neutropenia,
anemia,
thrombocytopenia,
clotting risks,
chemotherapy-induced nausea and vomiting, mucositis,
alopecia,
cognitive changes,
chemotherapy-induced peripheral neuropathy.
◉ S/E of Immunotherapy Monocle antibodies. Answer: allergic
reactions,
skin,
mucous membranes,
GI tract
QUESTIONS WITH SOLUTIONS
◉ Monoclonal antibodies(immunotherapy). Answer: Bind to target
antigens (often specific cell surface membrane proteins)
Prevents protein from functioning,
- prevents cell division. E.g- Rituximab (Rituxan)
◉ Tyrosine Kinase Inhibitors(immunotherapy). Answer: Inhibits
activation of tyrosine kinase inhibitors- disrupt growth and cellular
regulation of some types of cancer cells
◉ Epidermal Growth Factor/ Receptor Inhibitors(immunotherapy).
Answer: Block epidermal growth factor from binding to cell surface
receptor; prevents cancer cell division
◉ Vascular Endothelial Growth Factor/Receptor
Inhibitors(immunotherapy). Answer: prevents binding of VEGF with
its receptors on surfaces of endothelial cells present in blood
vessels. Prevents formation of new blood vessels within the tumor
◉ Multikinase Inhibitors (MKIs)(immunotherapy). Answer: Inhibit
activity of specific kinases in cancer cells and tumor blood vessels
,◉ Proteasome Inhibitor(immunotherapy). Answer: Prevents
formation of a large complex of proteins into cells; impair tumors
cellular regulation ability
◉ Angiogenesis inhibitors(immunotherapy). Answer: Targets
mammalian target of rapamycin; reduces concentration of vascular
endothelial growth factor, disrupts cell division.
◉ Photodynamic therapy. Answer: Selective destruction of cancer
cells via chemical reaction triggered by types of light
◉ Hormonal therapy. Answer: Changing usual hormone responses.
Some hormones make hormone sensitive tumors grow more rapidly
(Decreasing the hormone amounts to hormone sensitive tumors can
slow cancer growth rate).
Steroids, steroid analogues, enzyme inhibitors
◉ Surgical classification types. Answer: prophylaxis, diagnosis, cure,
control, palliation,assessing therapy effectiveness and
reconstruction
◉ Prophylaxis(Surgical classification type). Answer: remove
cancerous tissue to prevent cancer development
,◉ Diagnosis(Surgical classification type). Answer: removal for
testing or examination to rule out cancer "biopsy"
◉ Cure(Surgical classification type). Answer: removes all cancerous
tissue
◉ Control(Surgical classification type). Answer: removes part of
tumor when removal of entire tumor is impossible
◉ Palliation. Answer: surgery to provide symptom relief, is NOT
curative
◉ Assessing therapy effectiveness. Answer: (Surgical classification
type)
◉ Reconstruction(Surgical classification type). Answer: increases
function or appearance or both.
◉ S/E of Surgery. Answer: removal can lead to changes in
appearance, activity level, depression, grief, and decreased
enjoyment of life
, ◉ S/E of Radiation. Answer: Acute and long-term site-specific
changes, vary according to site, Local skin changes and hair loss,
altered taste sensations, Fatigue, Bone marrow suppression.
◉ S/E of Chemotherapy. Answer: extravasation,
infection risk,
bone marrow suppression,
neutropenia,
anemia,
thrombocytopenia,
clotting risks,
chemotherapy-induced nausea and vomiting, mucositis,
alopecia,
cognitive changes,
chemotherapy-induced peripheral neuropathy.
◉ S/E of Immunotherapy Monocle antibodies. Answer: allergic
reactions,
skin,
mucous membranes,
GI tract
